Form 4: Enanta Pharmaceuticals CEO Awarded Stock Options

Enanta Pharmaceuticals' CEO, Jay R. Luly, was granted 250,000 stock options on November 27, 2024, which vest over four years.

Summary

• Jay R. Luly, the President and CEO of Enanta Pharmaceuticals, was granted 250,000 stock options on November 27, 2024.
• The options have an exercise price of $8.83 per share.
• These options will vest quarterly in equal installments over four years, starting from the grant date.
• The options expire on November 27, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with company performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation across the pharmaceutical industry.
• The vesting schedule of four years is also typical, encouraging long-term commitment from the executive.
• The specific number of options and exercise price would need to be compared to similar companies to assess if it is in line with industry standards.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Enanta Pharmaceuticals, Jay R. Luly, vesting